# Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra® & Compare Both to a Vehicle Control in Treatment of Interdigital Tinea Pedis

> **NCT01580878** · PHASE1 · COMPLETED · sponsor: **Sun Pharmaceutical Industries, Inc.** · enrollment: 707 (actual)

## Conditions studied

- Tinea Pedis

## Interventions

- **DRUG:** Butenafine Hydrochloride Cream, 1%
- **DRUG:** Lotrimin Ultra®
- **DRUG:** Butenafine Vehicle

## Key facts

- **NCT ID:** NCT01580878
- **Lead sponsor:** Sun Pharmaceutical Industries, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2012-08
- **Final completion:** 2012-12
- **Target enrollment:** 707 (ACTUAL)
- **Last updated:** 2017-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01580878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01580878, "Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra® & Compare Both to a Vehicle Control in Treatment of Interdigital Tinea Pedis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01580878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*